Biocon Biologics 
Dealstreet

TT&A on $800 million Senior Secured Notes issue by Biocon Biologics Global

Biocon Biologics Global plc has made an issue and sale of $800 million 6.67% Senior Secured Notes due 2029.

Bar & Bench

Biocon Biologics Global plc, a wholly owned step down subsidiary of Biocon Biologics Limited, has made an issue and sale of $800 million Senior Secured Notes at 6.67% coupon rate which will be due in 2029.

The Bonds are expected to be rated BB by both S&P and Fitch and will be listed on the Singapore Stock Exchange. 

TT&A advised initial purchasers Merrill Lynch (Singapore) Pte. Ltd., Citigroup Global Markets Singapore Pte. Ltd., HSBC, Standard Chartered Bank (Singapore) Limited, BNP Paribas and Mizuho Securities (Singapore) Pte. Ltd. on this transaction.

The transaction team consisted of Rahul Gulati (Partner), Priyanka Kumar (Partner), Saara Ahmed (Managing Associate), Aakash Puttige (Senior Associate) and Shivani Iyer (Associate) Sushil Joon (Associate).

Rahul Gulati, Priyanka Kumar

The transaction represents the first US$ bond issuance by a biopharmaceutical company in Asia-Pacific, and the largest debut issuance from a high yield rated issuer from India in the past 10 years. It is also the debut overseas bond issuance by the Biocon group.

Also Read

Proof of motive not necessary to sustain murder charge: Delhi High Court

Can the blind see? Delhi High Court has a unique answer as it rules in favour blind candidate for AAI selection

Kerala lawyers object to Supreme Court view on High Courts entertaining anticipatory bail pleas ahead of sessions courts

Rajasthan High Court halts import and sale of GM food items until Centre frames regulations

AZB Senior Partner Sunila Awasthi leaves to join Lex Jurists

SCROLL FOR NEXT